Medicus Pharma Ltd. MDCX
Set alert
At close · Oct 30
After hours · Oct 30, 5:12 PM ET
- YTD
- -97.54%
- 1 year
- -98.48%
- Open
- 2.17
- Prev close
- 2.15
- Mkt cap
- 2.70M
- Vol
- 86.70K
- Avg vol
- 108.16K
- EPS
- -119.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.82
- High
- 2.18
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.52
- 200-d avg
- 2.52
- 1y target
- 7.81
5D chart
Signals (112)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 11:50 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:40 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:35 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:35 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:25 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:15 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:05 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:05 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 11:05 AM | 2 days ago |
| RSI: Oversold | Oct 30, 10:50 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:25 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:15 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:55 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:35 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:10 PM | 3 days ago |
| RSI: Oversold | Oct 29, 12:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:35 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 9:35 AM | 3 days ago |
| RSI: Oversold | Oct 29, 9:35 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:20 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:30 AM | 4 days ago |
| RSI: Oversold | Oct 28, 10:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:35 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| RSI: Oversold | Oct 27, 3:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:50 PM | 5 days ago |
| RSI: Overbought | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:55 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 11:55 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:55 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:25 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:25 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:15 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| RSI: Oversold | Oct 27, 9:45 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:30 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:30 PM | 6 days ago |
| RSI: Oversold | Oct 26, 2:00 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:45 PM | 6 days ago |
| RSI: Oversold | Oct 26, 1:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:55 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:20 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:35 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:25 AM | 6 days ago |
News
5 days ago globenewswire.com
Medicus Pharma to Present at BioFuture and Global Biotechnology Summit
Company's Executive Chairman and CEO to Speak on Cancer Therapeutics Spotlight Panel at BioFuture in NYC and Deliver Keynote Address at Global Biotechnology Summit in Abu Dhabi Company's Executive…
6 days ago globenewswire.com
Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Nasdaq closes the minimum bid price matter confirming that the Company has regained compliance Nasdaq closes the minimum bid price matter confirming that the Company has regained compliance
3 weeks ago benzinga.com
Dow Falls Over 100 Points; US Initial Jobless Claims Decline
U.S. stocks fell Thursday, led by tech, while energy rose and oil jumped 4.8%. Jobless claims eased to 197,000; small caps posted sharp swings.
3 weeks ago proactiveinvestors.com
Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances
Medicus Pharma (NASDAQ:MDCX) is positioning its precision oncology-led pipeline for a series of clinical and regulatory milestones, with partnerships and licensing deals central to the next phase of…
3 weeks ago globenewswire.com
Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
PHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and…
3 weeks ago benzinga.com
Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Applied Digital shares rise after Q1 revenue and loss beat estimates; Xiao-I and iPower lead gainers, while China SXT and Medicus Pharma fall.
3 weeks ago benzinga.com
Medicus Pharma (MDCX) Shares Fall 24% After Hours: Here's Why
Medicus Pharma shares fall 24% after hours as the company announces a 50-to-1 share consolidation.
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Valneva (NASDAQ:VALN) shares rose 20.6% to $7.09 during Wednesday's after-market session. The company's market cap stands at $555.6 million. Profound Medical (NASDAQ:PROF) stock rose 16.98%…
1 month ago proactiveinvestors.com
Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA
Medicus Pharma (NASDAQ:MDCX) has submitted a seamless Phase 2b/3 registration-intent protocol to the US Food and Drug Administration for Teverelix, its long-acting GnRH antagonist for advanced…
-
1 month ago benzinga.com
Medicus Pharma Files Optimized Seamless Phase 2b/3 Registration-Intent Protocol To FDA For Teverelix To Treat Advanced Prostate Cancer
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today…
1 month ago globenewswire.com
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company's capital-efficient development strategy…
1 month ago proactiveinvestors.com
Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients
Medicus Pharma (NASDAQ:MDCX) said it will focus future internally sponsored clinical development of SkinJect exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and…
1 month ago benzinga.com
Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus
Medicus Pharma narrows SkinJect development to Gorlin syndrome, targeting a $1.1 billion market and seeking key FDA orphan designations.
1 month ago globenewswire.com
Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
PHILADELPHIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd.
-
1 month ago benzinga.com
Medicus Pharma And Yorkville Mutually Agree To Terminate Standby Equity Purchase Agreement For Up To $15M Of Stock
On September 11, 2026, Medicus Pharma Ltd. (the "Company") and YA II PN, LTD. ("Yorkville") mutually agreed to terminate the Standby Equity Purchase Agreement, dated as of February 10, 2025, between…
1 month ago proactiveinvestors.com
Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress across its SkinJect program and a co-development and licensing opportunity with Pfizer, with CEO Raza Bokhari highlighting clinical,…
1 month ago proactiveinvestors.com
Wall Street sets positive tone as investors digest hotter inflation data
Positive tone Wall Street opened sharply higher on Friday, with the Dow Jones Industrial Average and S&P 500 both gaining 1.1% and the Nasdaq rising 1.2% as...
1 month ago proactiveinvestors.com
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment
Medicus Pharma (NASDAQ:MDCX) said a completed Phase 2 study of its SkinJect therapy showed all 90 enrolled patients finished treatment without discontinuations, data the company says will guide its…
-
1 month ago benzinga.com
Medicus Pharma Posts Phase 2 Clinical Study Report For SKNJCT‑003 On ClinicalTrials.gov, Offering Public Access To Efficacy, Safety, And Drug‑Delivery Findings
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today…
1 month ago globenewswire.com
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
CSR provides a clinical foundation for the Company's recently announced capital-efficient focus on FDA-authorized Gorlin Syndrome NDA-enabling development program while supporting partnership…
1 month ago proactiveinvestors.com
Dow falls as Treasury yields jump to highest level since 2023
10:05am: Rising yields pressure stocks Stocks moved lower at the open on Thursday as Treasury yields climbed to their highest level in years and oil prices...
1 month ago proactiveinvestors.com
Wall Street slips for a third straight day as oil and yields climb
4:20pm: Treasury yields climb Wall Street extended its selloff on Wednesday, with the Dow Jones Industrial Average falling 440 points as oil prices topped...
1 month ago proactiveinvestors.com
Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs
Medicus Pharma (NASDAQ:MDCX) is repositioning itself as a precision oncology-led biotechnology company, centering its strategy on CD228V, a second-generation antibody-drug conjugate targeting…
1 month ago globenewswire.com
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect® and Teverelix® indications Company prioritizes CD228V precision…
1 month ago benzinga.com
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Medicus Pharma Ltd. (NASDAQ:MDCX) secured on Wednesday an exclusive, sublicensable global license from Pfizer Inc. (NYSE:PFE) to develop, manufacture, and commercialize PF-08046031 (CD228V), an early…
1 month ago benzinga.com
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Medicus Pharma partners with Pfizer to commercialize CD228V in a licensing deal worth over $1 billion plus royalties.
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Cypherpunk Technologies (NASDAQ:CYPH) shares rose 30.4% to $2.19 during Thursday's regular session. The market value of their outstanding shares is at $181.0 million. bioAffinity Technologies…
1 month ago benzinga.com
Nasdaq Gains Over 200 Points; US Weekly Jobless Claims Edge Higher
U.S. stocks climbed, led by Nasdaq; communications shares rose, energy fell, while MIMI surged and RARE plunged after trial failures.
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market session. The company's market cap stands at $7.4 million. bioAffinity Technologies (NASDAQ:BIAF) shares…
2 months ago proactiveinvestors.com
Medicus Pharma advances pipeline during Q2 with key milestones
Medicus Pharma (NASDAQ:MDCX) has reported second quarter financial results and regulatory and clinical progress across its SkinJect and Teverelix programs, while raising about $40 million through…
-
2 months ago benzinga.com
Medicus Pharma Q2 EPS $(0.21) Misses $(0.13) Estimate
Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.13) by 61.54 percent. This is a 51.16 percent increase over losses of…
2 months ago accessnewswire.com
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Company Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect® and Teverelix® Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and…
2 months ago proactiveinvestors.com
SK Hynix backed by Wedbush as memory undersupply persists
SK Hynix Inc (NASDAQ:SKHY) has received an ‘Outperform’ rating from Wedbush on Tuesday as the firm initiated coverage with a KRW2.56 million price target,...
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 91.1% to $6.04 during Friday's after-market session. The company's market cap stands at $2.2 million. BGM Group (NASDAQ:BGM) stock…
3 months ago benzinga.com
EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi
Medicus Pharma obtained UAE approval for its PRECISION-E2 Phase 2a clinical trial testing Teverelix in endometriosis patients.
-
3 months ago benzinga.com
Medicus Pharma Receives FDA's Study May Proceed Letter Authorization For Its Investigational New Drug For SKNJCT-005 To Start Phase 2b Clinical Study To Treat Gorlin Syndrome
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 41.1% to $0.09 during Friday's after-market session. The market value of their outstanding shares is at $12.7 million. iTonic…
-
3 months ago benzinga.com
Medicus Pharma Announces Positive FDA Feedback For Its Optimized Phase 2 Clinical Trial Of Teverelix In Men Following A First Episode Of Acute Urinary Retention
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 56.1% to $4.62 during Monday's after-market session. The company's market cap stands at $1.7 million. Medicus Pharma (NASDAQ:MDCX) stock rose…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ:HUMA) shares moved upwards by 5.45% to…
-
4 months ago benzinga.com
Medicus Pharma To Highlight SkinJect Phase 2 Data And Teverelix Clinical Advances At BIO 2026
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
4 months ago benzinga.com
Medicus Pharma Files Rare Pediatric Disease Designation Request To FDA For SkinJect Microneedle Array Patch To Treat Basal Cell Carcinoma In Participants With Gorlin Syndrome
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic…
-
4 months ago benzinga.com
Medicus Pharma Submits IND Application To DOH For PRECISION-E2, Phase 2a Genomics-Enabled Clinical Trial Evaluating Teverelix In Women With Symptomatic Endometriosis In UAE
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic…
-
4 months ago benzinga.com
Medicus Pharma Submits Modification Application Through European Union Clinical Trials Information System For Its Phase 2b Trial Of Teverelix In Advanced Prostate Cancer
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive…
-
5 months ago benzinga.com
Medicus Pharma Submits Protocol SKNJCT-005 To FDA Under Existing IND Application, For SkinJect Into Registrational Development For Patients With Gorlin Syndrome
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics…
-
5 months ago benzinga.com
Medicus Pharma Receives $22M In Non-Dilutive Financing
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics…
-
5 months ago benzinga.com
Medicus Pharma Q1 EPS $(0.31) Misses $(0.19) Estimate
Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.19) by 63.16 percent. This is a 26.19 percent increase over losses of…
5 months ago benzinga.com
EXCLUSIVE: Medicus Sees Strongest Efficacy At Higher Dose In Skin Cancer Study
Medicus Pharma reports dose-response in Phase 2 BCC study, with 200µg cohort showing the strongest efficacy and safety profile at Day 57.
-
5 months ago benzinga.com
Medicus Pharma Highlights Results From Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis; Says Data Reveal 'a clear and consistent dose-response relationship across endpoints'
200μg Cohort Achieves 55% Complete Response at Day 57 Emerging asRegistrational Grade Lead RegimenThe pre-specified expanded dataset analysis builds on this foundation by: Revealing a clear and…